Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer | BMC Cancer | Full Text

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer | BMC Cancer | Full Text

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer

While epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert a breakthrough effect, the incidence of skin disorders as a side effect has significantly reduced patients’ quality of life...

Authors:Kazumi Sano, Kazuhiko Nakadate and Kazuhiko Hanada

Citation:BMC Cancer 2020 20:279

Content type:Research article

Published on: 6 April 2020

• ViewFull Text
 
• ViewPDF